



Regulatory Updates in Taiwan

October, 20th, 2022

**Speaker : Dr. Shou-Mei Wu, Director-General
Taiwan Food and Drug Administration (TFDA)**



Outline

1

Medicinal Products

2

Medical Devices

3

Collaboration with Japan

4

Future Prospects



Emergency Use Authorization for COVID-19 Vaccines/Drugs

VACCINES

Comirnaty[®] of Pfizer/BNT

Spikevax[®] of Moderna

Spikevax[®] bivalent
of Moderna

Vaxzevria[®] of AstraZeneca

Nuvaxovid[®] of Novavax

MVC-COV1901 of Medigen

Drugs

Remdesivir of Gilead

Paxlovid[®] of Pfizer

Molnupiravir of MSD

Evusheld of AstraZeneca



Three Draft Acts for Regenerative Medicine

Drafts announced on Jan 13, 2022

**Regenerative Medicine
Development Act (draft)**
再生醫療發展法

To facilitate the development of RM in Taiwan



**Regenerative Medicine
Therapy Act (draft)**
再生醫療施行及管理條例

To regulate the clinical practice of
RM therapy at medical institute



**Regenerative Medicine
Product Act (draft)**
再生醫療製劑管理條例

To regulate the life-cycle
of RM products

Real-World Data and Evidence in Drug Application – Guidelines in Taiwan

Basic Considerations in Supporting Drug Research and Development with Real-World Evidence

Jul 2020

Real World Data Quality Evaluation- Relevance and Reliability Considerations

Mar 2021

Precautions for submitting technical documents using RWD/RWE for drug application

Jul 2021

Registration

R&D

Clinical Trial

Post-Market Pharmacovigilance

Use of Electronic Medical Record Data in Clinical Studies

Nov 2020

RWE Study Designs- Considerations and Key Points for Pragmatic Clinical Trial

Jan 2021

Guidelines for Using Electronic Healthcare Data to Conduct Pharmacoeconomic Safety Studies

Mar 2022(Draft)



衛生福利部
食品藥物管理署
Taiwan Food and Drug Administration

Drug Safety Monitoring

Revise regulations for Drug Safety Monitoring

2022.04.15

01

PV Range

Require all of MAH should implement PV system.

02

Risk Management

Require MAH should report when finding an emerging safety issue from any source and take actions.



03

PV Master file

- Draw reporting format.
- If the transfer of MAH shall hand over the safety information to the transferee, and the transferee shall continue to conduct the surveillance or storage .

04

PV Inspection

Government could inspect MAH to make sure they implement PV.




*MAH: Marketing Authorization Holder




衛生福利部
食品藥物管理署
Taiwan Food and Drug Administration


Regulatory updates in clinical trials


2021.10  Revised Principles of Clinical Trial Recruitments


2021.10  Planning and Design of Multi-Regional Clinical Trials


2021.10  Biopharmaceutics Classification System-Based Biowaivers

2022.06  Guideline on Quality and Equivalence Of Topical Products (Draft)


2022.06  Guideline on Equivalence of Locally Applied, Locally Acting Products in The Gastrointestinal Tract (Draft)

2022.07  Guidance on Considerations for Sex Differences Analyses in Clinical Trials (Draft)


2022.08  Clinical Evaluation of QT/QtC Interval Prolongation and Proarrhythmic Potential for Non-antiarrhythmic Drugs and Q&A (Draft)

2022.08  Guideline on Genomic Sampling and Management of Genomic Data (Draft)

2022.08  Development Safety Update Report



Prospects for the application of drug e-labeling



Standardize labeling formats

Pilot Program: Replacing package insert of specific drugs with e-Labeling

Optimize the operational platform at the new system



Edit structured e-labeling by pharmaceutical companies

Design the XML format standards of structured e-labeling and release to the public



Establishment of a Dedicated Office for AI Medical Device

Inauguration on May 7, 2021




Implement consultation for **domestic AI-based MD**



Establish an AI/ML MD information and matchmaking platform



Conduct training and promotion activities



Provide assistance in **developing relevant policies and guidances**

Related Documents for SaMDs

Totally 17 documents

1 Reference Template

Cybersecurity Evaluation Analysis

11 Guidances

Categorization and Classification

QMS

Validation

Cybersecurity

.....etc

Registration

- AI/ML-based SaMD
- CADt SaMD
- CADe/CADx SaMD
- NSR Clinical Trial

5 FAQ

Registration AI/ML MD

QMS Compliance

.....etc

SaMD : Software as Medical Device
QMS : Quality Management System
NSR : Nonsignificant risk

CADt : Computer Aided Triage
CADe : Computer Aided Detection
CADx : Computer Aided Diagnosis


Examples of Approved, Domestic AI-based SaMDs

Totally 54 AI-based SaMDs have been approved.
(From 2020 to 2022.9)




VeriSee DR

Identify the **Diabetic Retinopathy**



acer
Medical


Domestic
(15, 28%)



Imported
(39, 72%)

aetherAI Hema

Identify, classify and count the types and numbers of **bone marrow cells**.



aetherAI
雲象科技



Bu-CAD

Analyze the breast ultrasound images of patients with **soft tissue breast lesions** suspicious for breast cancer




TaiHao
Medical Inc.



DeepMets

Provide initial **contours of diagnosed brain metastases** on MR images.




TAIMeding



ECG-EC-100

Identify 12 types of **arrhythmia and acute myocardial infarction** from 12-lead electrocardiograms (EKG / ECG).



EVER
FORTUNE.AI



衛生福利部
食品藥物管理署
Taiwan Food and Drug Administration



Collaboration with Japan




Pharmaceutical Working Group

- ✓ Completed **Position Paper** (NDA review and registration), **Five cases have completed**.
- ✓ Established the **Information Sharing** model of post-marketing surveillance information.



Medical Devices Working Group

1. Established a **position paper** aimed to continuously collaborate and renew the **Q&As of products registration for the benefit of stakeholders**
2. Updated the regulations or guidelines relating to **cybersecurity, artificial intelligence/machine learning** medical devices



Progress for the QMS Working Group of Medical Devices



Till September 06, 2022,
44 manufacturers were
approved under
abbreviated mode.



Q&A for MOC was published
on December 21.

MOC was signed on November 30.

2020

2022



2018

2019

Abbreviated mode
start up.

2014

Establishment of QMS WG.



衛生福利部
食品藥物管理署
Taiwan Food and Drug Administration

Future Prospects

Foresighted-
Legislation

Accessible
Information
Platform

Professional
Review Team

Quality
Compliance and
Management

Efficient
Communication
and Services

International
Regulatory
Collaboration



ありがとう!

Thank You!



衛生福利部
食品藥物管理署
Taiwan Food and Drug Administration

<http://www.fda.gov.tw/>